The DNA-PKcs and phospho-DNA-PKcs expression levels also decreased after application of 47Sc-DTPA-cetuximab (Fig. 4D), suggesting that EGFR-overexpressing NSCLC cells are more sensitive to anticancer therapy following 47Sc-DTPA-cetuximab treatment. This evidence concerns the gene PRKDC and non-small cell lung carcinoma.